Objective: To estimate the CER of three health care delivery models (HCDM) for HIV+ patients in Colombia. Methods: A review of 356 medical records from patients affiliated to institutions under the Contributive Regimen in the Colombian Health System was performed. The review incorporates data from 2002 to 2005, including disease status, treatment efficacy, and costs of care. VL and CD4 count data from the three-year analysis were used as clinical outcomes. Direct costs included medications, hospital expenses, doctor visits, laboratory tests, and other health care providers costs. Description of the three models and analyses of the services provided, team members, negotiations by plan were described for each model. Results: AFter controlling by disease status and services utilization increase of CD4 count over the time of the study was significantly lower for patients in Model 3 (mean+238cells/mm3) than Model 1 (mean+649cells/mm3) and Model 2 (mean+676 cells/mm3). When VL was analyzed patients in Model 1 had a higher decrease in VL levels -118,290 RNA copies vs. Model 2:- 33,693 RNA copies and Model 3=-33,504 RNA copies. Cost related to hospitalizations were comparable in the three models and high differences were found in the utilization and cost of outpatient services. However the overall cost including antiretrovirals for patients in Model 1 was $10,399.00, $11,617 for Model 2 and $11,002 for Model 3. After a sensitivity analyses was performed CER were calculated. The lower CER was $16.7 per CD4cell/mm3 increased and $0.20 per RNA copies decreased in Model 2 compared to $19 and $0.30 for Model 1 and $26 and $0.58 for Model 3. Conclusion: CONCLUSIONS: Due to differences in the plan characteristics and services utilization of the Health Care Delivery Models, Model 2 appears to be a highly cost-effective program relative to Model 1 and 3 health care programs for HIV patients in Colombia.